KEGG   PATHWAY: pleu05235
Entry
pleu05235                   Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Peromyscus leucopus (white-footed mouse)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
pleu05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
pleu05235

Organism
Peromyscus leucopus (white-footed mouse) [GN:pleu]
Gene
114681035  Nfatc3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X1 [KO:K17333]
114681524  Akt2; RAC-beta serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
114681906  Ptpn11; LOW QUALITY PROTEIN: tyrosine-protein phosphatase non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
114682099  Rela; transcription factor p65 [KO:K04735]
114682127  Batf2; LOW QUALITY PROTEIN: basic leucine zipper transcriptional factor ATF-like 2 [KO:K09034]
114682485  Cd28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
114682503  Myd88; myeloid differentiation primary response protein MyD88 [KO:K04729]
114682692  Egf; pro-epidermal growth factor [KO:K04357]
114682732  Mapk1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
114682786  Stat3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
114683205  Nfkb1; nuclear factor NF-kappa-B p105 subunit [KO:K02580]
114683255  Ppp3ca; serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
114683276  Map2k3; dual specificity mitogen-activated protein kinase kinase 3 isoform X1 [KO:K04432] [EC:2.7.12.2]
114683746  Hif1a; hypoxia-inducible factor 1-alpha isoform X1 [KO:K08268]
114684032  Pik3cd; LOW QUALITY PROTEIN: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform [KO:K00922] [EC:2.7.1.153]
114684433  Nfatc2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332]
114684706  Nfkbib; NF-kappa-B inhibitor beta [KO:K02581]
114685101  Ticam1; LOW QUALITY PROTEIN: TIR domain-containing adapter molecule 1 [KO:K05842]
114685127  [KO:K02833]
114685999  Rps6kb2; ribosomal protein S6 kinase beta-2 isoform X1 [KO:K04688] [EC:2.7.11.1]
114686090  [KO:K05132]
114686570  Ppp3r2; calcineurin subunit B type 2 [KO:K06268]
114688121  Map2k2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
114688488  [KO:K02833]
114688966  Pik3r2; phosphatidylinositol 3-kinase regulatory subunit beta isoform X1 [KO:K02649]
114689636  Raf1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
114689925  Cd247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
114690404  Map3k3; mitogen-activated protein kinase kinase kinase 3 isoform X3 [KO:K04421] [EC:2.7.11.25]
114690458  Map2k6; dual specificity mitogen-activated protein kinase kinase 6 isoform X1 [KO:K04433] [EC:2.7.12.2]
114690660  Akt3; RAC-gamma serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
114690779  [KO:K07360] [EC:2.7.10.2]
114691293  Cd3g; T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
114691294  Cd3d; T-cell surface glycoprotein CD3 delta chain [KO:K06450]
114691295  Cd3e; T-cell surface glycoprotein CD3 epsilon chain [KO:K06451]
114691497  Map2k1; dual specificity mitogen-activated protein kinase kinase 1 isoform X2 [KO:K04368] [EC:2.7.12.2]
114692579  Plcg1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 [KO:K01116] [EC:3.1.4.11]
114693019  Mapk12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
114693020  Mapk11; mitogen-activated protein kinase 11 isoform X5 [KO:K04441] [EC:2.7.11.24]
114693330  Ifng; interferon gamma [KO:K04687]
114693378  Nfkbia; NF-kappa-B inhibitor alpha [KO:K04734]
114693493  [KO:K02833]
114693559  Pik3cb; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
114693595  Hras; GTPase HRas isoform X1 [KO:K02833]
114693732  Jak1; LOW QUALITY PROTEIN: tyrosine-protein kinase JAK1 [KO:K11217] [EC:2.7.10.2]
114693768  Jun; transcription factor AP-1 [KO:K04448]
114694482  Csnk2a2; casein kinase II subunit alpha' isoform X1 [KO:K03097] [EC:2.7.11.1]
114694913  Nfatc1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X1 [KO:K04446]
114695335  Pik3ca; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
114696211  [KO:K05119] [EC:2.7.10.1]
114696553  [KO:K02833]
114697520  [KO:K04350]
114698038  Fos; proto-oncogene c-Fos [KO:K04379]
114698208  Batf3; basic leucine zipper transcriptional factor ATF-like 3 [KO:K09034]
114698434  Ifngr2; interferon gamma receptor 2 isoform X1 [KO:K05133]
114698582  Nras; GTPase NRas [KO:K07828]
114698768  Ppp3cc; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform [KO:K04348] [EC:3.1.3.16]
114698806  [KO:K04348] [EC:3.1.3.16]
114698971  Batf; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
114699281  Rps6kb1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
114699775  [KO:K05403]
114700198  Ppp3cb; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
114700306  Lat; linker for activation of T-cells family member 1 isoform X1 [KO:K07362]
114703046  Akt1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
114703850  Pik3r1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
114704332  Mapk3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
114705035  Stat1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
114705519  Ppp3r1; calcineurin subunit B type 1 isoform X2 [KO:K06268]
114705532  Egfr; epidermal growth factor receptor isoform X1 [KO:K04361] [EC:2.7.10.1]
114705599  Csnk2a1; LOW QUALITY PROTEIN: casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
114705667  Lck; tyrosine-protein kinase Lck [KO:K05856] [EC:2.7.10.2]
114705738  Ikbkb; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X1 [KO:K07209] [EC:2.7.11.10]
114705782  Tlr4; toll-like receptor 4 isoform X2 [KO:K10160]
114705884  Csnk2b; casein kinase II subunit beta isoform X1 [KO:K03115]
114705910  [KO:K04350]
114706162  Mapk13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
114706165  Mapk14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
114706175  Ikbkg; NF-kappa-B essential modulator isoform X1 [KO:K07210]
114706431  Chuk; inhibitor of nuclear factor kappa-B kinase subunit alpha isoform X1 [KO:K04467] [EC:2.7.11.10]
114706924  Pik3r3; phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649]
114707807  Pdcd1; programmed cell death protein 1 isoform X1 [KO:K06744]
114707855  Nfkbie; NF-kappa-B inhibitor epsilon [KO:K05872]
114707943  [KO:K03097] [EC:2.7.11.1]
114708252  Prkcq; protein kinase C theta type isoform X1 [KO:K18052] [EC:2.7.11.13]
114708477  Kras; GTPase KRas isoform X2 [KO:K07827]
114708811  Ptpn6; tyrosine-protein phosphatase non-receptor type 6 isoform X1 [KO:K05697] [EC:3.1.3.48]
114708820  Cd4; T-cell surface glycoprotein CD4 isoform X2 [KO:K06454]
114708904  Eml4; LOW QUALITY PROTEIN: echinoderm microtubule-associated protein-like 4 [KO:K15420]
114709670  Mtor; LOW QUALITY PROTEIN: serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
114710188  Tlr2; toll-like receptor 2 [KO:K10159]
114710385  Jak2; tyrosine-protein kinase JAK2 [KO:K04447] [EC:2.7.10.2]
114710411  Cd274; programmed cell death 1 ligand 1 [KO:K06745]
114710523  [KO:K04371] [EC:2.7.11.24]
114710754  Traf6; TNF receptor-associated factor 6 [KO:K03175] [EC:2.3.2.27]
114710991  Tlr9; toll-like receptor 9 isoform X1 [KO:K10161]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
pleu04010  MAPK signaling pathway
pleu04020  Calcium signaling pathway
pleu04066  HIF-1 signaling pathway
pleu04151  PI3K-Akt signaling pathway
pleu04514  Cell adhesion molecule (CAM) interaction
pleu04620  Toll-like receptor signaling pathway
pleu04660  T cell receptor signaling pathway
KO pathway
ko05235   

DBGET integrated database retrieval system